

AGE Reader Key Publications

- **Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study.**
van Waateringe R. et al. Eur J Clin Invest. 2016 Mar 22. Epub.
- **Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus.**
Lutgers H. et al, Diabetologia, 2009; 52(5): 789-797
- **Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study.**
Noordzij M.J. et al. Diabet Med. 2012 Dec;29(12):1556-61.
- **Skin Autofluorescence and the Association with Renal and Cardiovascular Risk Factors in Chronic Kidney Disease Stage 3.**
McIntyre N. et al. Clin J Am Soc Nephrol. 2011 Sep 1. Epub
- **Skin Autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular disease.**
Gerrits E. et al. Diabetes Care. 2008; 31: 517-521
- **Messung der Autofluoreszenz der Haut.**
Stirban A. and Heinemann L. Diabetes Stoffw Herz. 2013; 22 (full text available)
- **Skin Autofluorescence Is Associated With 5-Year Mortality and Cardiovascular Events in Patients With Peripheral Artery Disease.**
de Vos LC. et al. Arterioscler Thromb Vasc Biol. 2014 Feb 13.
- **Simple non-invasive assessment of advanced glycation endproducts accumulation.**
Meerwaldt R et al, Diabetologia, 2004; 47:1324-1330

AGE Reader in diabetes

1. **Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes.**
Fokkens BT, Smit AJ. Glycoconj J. 2016 Aug;33(4):527-35.
2. **ADVANCED GLYCATION END PRODUCT (AGE) ACCUMULATION IN THE SKIN IS ASSOCIATED WITH DEPRESSION: THE MAASTRICHT STUDY.** van Dooren FE et al. Depress Anxiety. 2016 Jun 6. (Epub)
3. **Skin autofluorescence and peripheral neuropathy four years later in type 1 diabetes.**
Rajaobelina K. et al. Diabetes Metab Res Rev. 2016 May 27. Epub
4. **The relationship between advanced glycation endproducts and ocular circulation in type 2 diabetes.**
Hashimoto K. et al. J Diabetes Complications 2016 May 4. Epub.
5. **Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes.**
Furst J.R. et al. J Clin Endocrinol Metab. 2016 Apr 26. Epub.
6. **Association of Advanced Glycation End Products with coronary Artery Calcification in Japanese Subjects with Type 2 Diabetes as Assessed by Skin Autofluorescence.**
Hangai M. et al. J Atheroscler Thromb. 2016 Mar 10.
7. **Non-invasive Measurement of Skin Autofluorescence as a Beneficial Surrogate Marker for Atherosclerosis in Patients with Type 2 Diabetes.**
Temma J. et al. J Med Invest. 2015;62(3-4):126-9.
8. **Advanced glycation end products, measured in skin, vs. HbA1c in children with type 1 diabetes mellitus.**
Banser A. et al. Pediatr Diabetes. 2015 Sep 2.

- 9. Relationship between skin auto fluorescence and conventional glycemic markers in patients with diabetes.**
Mácsai E. et al. *Orv Hetil.* 2015 Aug 16;156(33):1341-7.
- 10. In diabetic Charcot neuroarthropathy impaired microvascular function is related to long lasting metabolic control and low grade inflammatory process.**
Araszkiwicz A. et al. *Microvasc Res.* 2015 Aug 1;101:143-147.
- 11. Vitamin D status is associated with skin autofluorescence in patients with type 2 diabetes mellitus: a preliminary report.**
Krul-Poel Y.H. et al. *Cardiovasc Diabetol.* 2015 Jul 16;14:89.
- 12. Is skin autofluorescence a marker of metabolic memory in pregnant women with diabetes?**
Maury E. et al. *Diabet Med.* 2015 May 16.
- 13. The Association Between Skin Autofluorescence and Vascular Complications in Chinese Patients With Diabetic Foot Ulcer: An Observational Study Done in Shanghai.**
Liu C. et al. *Int J Low Extrem Wounds.* 2015. (Epub)
- 14. Autofluorescence of Skin Advanced Glycation End Products: Marker of Metabolic Memory in Elderly Population.**
Rajaobelina K. et al. *J Gerontol A Biol Sci Med Sci.* 2015 Jan 14 (Epub)
- 15. Skin autofluorescence is associated with carotid intima-media thickness, diabetic microangiopathy, and long-lasting metabolic control in type 1 diabetic patients. Results from Poznan Prospective Study.**
Araszkiwicz A. et al. *Microvasc Res.* 2015 Jan 10 (Epub)
- 16. Association of advanced glycation end products and chronic kidney disease with macroangiopathy in type 2 diabetes.**
Rigalleau V. et al. *J Diabetes Complications.* 2014 Oct 30. Epub
- 17. Advanced glycation end products (AGEs) and the soluble receptor for AGE (sRAGE) in patients with type 1 diabetes and coeliac disease.**
Bakker S.F. et al. *Nutr Metab Cardiovasc Dis.* 2014 Nov 1. Epub
- 18. Associations of advanced glycation endproducts with cognitive functions in individuals with and without type 2 diabetes.**
Spauwen P.J. et al. *J Clin Endocrinol Metab.* 2014 Dec 2
- 19. Relationship of Skin Autofluorescence to Severity of Retinopathy in Type 2 Diabetes.**
Yasuda M. et al. *Curr Eye Res.* 2014 May 28:1-8.
- 20. Type 2 diabetes mellitus, skin autofluorescence and brain atrophy.**
Moran C. et al. *Diabetes.* 2014 Jul 22.
- 21. AGEs and chronic subclinical inflammation in diabetes: disorders of immune system.**
Hu H. et al. *Diabetes Metab Res Rev.* 2014 May 20. Epub
- 22. Correlation between diabetic makuls severity and elevated skin autofluorescence as a marker of advanced glycation end-product accumulation in type 2 diabetic patients.**
Hirano T. et al. *J Diabetes Complications.* 2014 Mar 10. Epub
- 23. Advanced glycation end products are associated with arterial stiffness in type 1 diabetes.**
Llauradó G. et al. *J Endocrinol.* 2014 Jun;221(3):405-13.
- 24. Messung der Autofluoreszenz der Haut.**
Stirban A. and Heinemann L. *Diabetes Stoffw Herz.* 2013; 22 (full text available)
- 25. Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus.**
Skrha J Jr. et al. *J Diabetes Res.* Epub 2013 Mar 10.
- 26. Skin autofluorescence based decision tree in detection of impaired glucose tolerance and diabetes.**
Smit AJ. et al. *PLoS One.* 2013 Jun 4;8(6):e65592.
- 27. Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis.**
Fukami K. *Rejuvenation Res.* 2013 Aug 4. [Epub ahead of print]

28. **Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus.**
Skrha J Jr. et al. *J Diabetes Res.* 2013;2013:650694.
29. **Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus.**
Genevieve M. et al. *Diabetes Metab.* 2013 May 2. [Epub ahead of print]
30. **Advanced Glycation End Products Assessed by Skin Autofluorescence-A New Marker of Diabetic Foot Ulceration.**
Vouillarmet J. et al. *Diabetes Technol Ther.* 2013 Apr 30. [Epub ahead of print]
31. **Study design of DIACORE (DIAbetes COHoRtE) - a cohort study of patients with diabetes mellitus type 2.**
Dörhöfer L, *BMC Med Genet.* 2013 Feb 14;14:25.
32. **Verification of Skin Autofluorescence Values by Mass Spectrometry in Adolescents with Type 1 Diabetes: Brief Report.**
Mácsai E. et al. *Diabetes Technol Ther.* 2013 Jan 23.
33. **Advanced glycation end products in infant formulas do not contribute to insulin resistance associated with their consumption.**
Klenovics KS. et al. *PLoS One.* 2013;8(1):e53056.
34. **Advanced Glycation End Products, Measured as Skin Autofluorescence, During Normal Pregnancy and Pregnancy Complicated by Diabetes Mellitus.**
de Ranitz-Greven WL. et al. *Diabetes Technol Ther.* 2012 Oct 31. (Epub)
35. **Skin autofluorescence measurement in diabetological and nephrological clinical practice.**
Mácsai E. et al. *Orv Hetil.* 2012 Oct 21;153(42):1651-7.
36. **Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study.**
Noordzij M.J. et al. *Diabet Med.* 2012 Aug 31. doi: 10.1111/dme.12005.
37. **Advanced glycation end products measured by skin autofluorescence in a population with central obesity.**
den Engelsen C. et al. *Dermatoendocrinol.* 2012 Jan 1;4(1):33-8.
38. **Elevated skin autofluorescence is strongly associated with foot ulcers in patients with diabetes: a cross-sectional, observational study of Chinese subjects.**
Hu H. et al. *J Zhejiang Univ Sci B.* 2012 May;13(5):372-7.
39. **Advanced Glycation Endproducts and Diabetic Cardiovascular Disease.**
Prasad A. et al. *Cardiol Rev.* 2012 Feb 6. Epub
40. **Non-invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction.**
Januszewski A.S. et al. *Diabet Med.* 2011 Dec 28. doi: 10.1111/j.1464-5491.2011.03562.x.
41. **Skin autofluorescence is associated with severity of vascular complications in Japanese patients with Type 2 diabetes.** Tanaka K. et al. *Diabet Med.* 2011 Sep 14. Epub
42. **Skin autofluorescence is inversely related to HDL anti-oxidative capacity in type 2 diabetes mellitus.**
Mulder D. et al. *Atherosclerosis.* 2011 May, Epub
43. **Advanced Glycation End Products, Measured as Skin Autofluorescence, at Diagnosis in Gestational Diabetes Mellitus Compared with Normal Pregnancy.**
de Ranitz-Greven WL et al. *Diabetes Technol Ther.* 2011 Aug 29. Epub
44. **Increased accumulation of skin advanced glycation end products is associated with microvascular complications in type 1 diabetes.**
Araszkiewicz A. et al. *Diabetes Technol Ther.* 2011 Aug;13(8):837-42.
45. **Assessment of skin autofluorescence as a marker of advanced glycation end product accumulation in type 1 diabetes.**
Samborski P. et al. *Pol Arch Med Wewn.* 2011 Mar;121(3):67-72.

46. **Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review.**
Bos D.C. et al. *Diabetes Technol Ther.* 2011 Jul;13(7):773-9.
47. **Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients.**
Willemsen S. et al. *Eur J. Heart Fail* 2010. doi:10.1093/eurjhf/hfq168
48. **Skin autofluorescence and glycemic variability.**
Noordzij M. et al. *Diabetes Technol Ther.* 2010; 12(7): 581-585
49. **Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy.**
Chabroux S. et al: *Diabetes Metab*, 2010 Apr;36(2):152-7.
50. **Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus**
Lutgers H. et al: *Diabetologia*, 2009; 52(5): 789-797
51. **Skin Autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular disease.**
Gerrits E. et al. *Diabetes Care.* 2008; 31: 517-521
52. **Skin autofluorescence is a strong predictor of cardiac mortality in diabetes**
Meerwaldt R, et al. *Diabetes Care* 2007, 30: 107-112
53. **Skin autofluorescence in type 2 diabetes: Beyond blood glucose**
Monami M. et al. *Diabetes Research & Clinical Practice* July 2007. epub
54. **Non-invasive AGE-measurements by skin autofluorescence in patients with Type 2 Diabetes Mellitus. Tool for risk-assessment of diabetes complications?**
Lutgers H, et al. *Diabetes Care.* 2006 Dec;29(12):2654-9
55. **Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy**
Meerwaldt R, et al. *Diabetologia.* 2005;48:1637-44.
56. **The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceuticals to reduce AGE accumulation.**
Smit AJ, Lutgers HL. *Curr Med Chem.* 2004 Oct;11(20):2767-84.

AGE Reader in cardiovascular disease

57. **Association of Skin Autofluorescence Levels With Kidney Function Decline in Patients With Peripheral Artery Disease.**
Schutte E et al. *Arterioscler Thromb Vasc Biol.* 2016 Aug;36(8):1709-14.
58. **The Relationship Between Level of End-Products of Tissue Glycation and Pulse Wave Velocity in Non-diabetic Patients With Cardiovascular Disease.**
Ageev F.T. et al. *Kardiologija.* 2015;55(6):63-7.
59. **Skin autofluorescence as a measure of advanced glycation end products deposition predicts 5-year amputation in patients with peripheral artery disease.**
de Vos LC. et al. *Arterioscler Thromb Vasc Biol.* 2015 Jun;35(6):1532-7.
60. **Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease.**
Yamagishi S.I. et al. *Int J Cardiol.* 2015 Mar (Epub)
61. **Skin autofluorescence, 5-year mortality, and cardiovascular events in peripheral arterial disease: all that glitters is surely not gold.**
Schmidt AM. *Arterioscler Thromb Vasc Biol.* 2014 Apr;34(4):697-9.

62. **Skin Autofluorescence Is Associated With 5-Year Mortality and Cardiovascular Events in Patients With Peripheral Artery Disease.**
de Vos LC. et al. *Arterioscler Thromb Vasc Biol.* 2014 Feb 13.
63. **Skin Autofluorescence, a Non-Invasive Marker for AGE Accumulation, Is Associated with the Degree of Atherosclerosis.**
den Dekker MA. et al. *PLoS One.* 2013 Dec 23;8(12):e83084.
64. **Skin autofluorescence as proxy of tissue AGE accumulation is dissociated from SCORE cardiovascular risk score, and remains so after 3 years.**
Tiessen AH. et al. *Clin Chem Lab Med.* 2013 Apr 2:1-7.
65. **Skin Autofluorescence as a Measure of Advanced Glycation End Product Deposition Is Elevated in Peripheral Artery Disease.**
de Vos L.C. et al. *Arterioscler Thromb Vasc Biol.* 2012 Nov 8. (Epub)
66. **Relationship between tissue glycation measured by autofluorescence and pulse wave velocity in young and elderly non-diabetic populations.**
Watfa G. et al. *Diabetes Metab.* 2012 Jun 13.
67. **Advanced glycation end product associated skin autofluorescence: A mirror of vascular function?**
Hofmann B. et al. *Exp Gerontol.* 2012 May 12.
68. **Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.**
Hartog J.W. et al. BENEFICIAL investigators. *Eur J Heart Fail.* 2011 Aug;13(8):899-908.
69. **Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease.**
Noordzij MJ. *Int J Cardiovasc Imaging.* 2011 Feb. Epub
70. **Carotid artery intima media thickness associates with skin autofluorescence in non-diabetic subjects without clinically manifest cardiovascular disease.**
Lutgers H. et al. *Eur J Clin Invest.* 2010 ;40(9):812-7
71. **Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction.**
Hartog J. et al; *Eur. Journal of Heart Failure*, 2010 Apr;12(4):397-403
72. **Advanced glycation end products in patients with cerebral infarction.**
Ohnuki Y. *Intern Med.* 2009;48(8):587-91.
73. **Advanced Glycation End Products and their receptor RAGE in systemic autoimmune diseases - an inflammation propagating factor contributing to accelerated atherosclerosis.**
Nienhuis et al. *Autoimmunity*, 2009; 42(4): 302-304
74. **Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events**
Mulder D. et al, *Netherlands Heart Journal*, Volume 17, Number 4, April 2009
75. **Relation between food and drinking habits, and skin autofluorescence and intima media thickness in subjects at high cardiovascular risk**
Jochemsen M. et al: *Journal of Food and Nutrition Research* Vol. 48, 2009, No. 1, pp. 51–58
76. **Advanced Glycation Endproducts (AGE) in chronic heart failure**
Smit A. et al. *Annals of New York Academy of Science* 2008; 1126:225-30
77. **Clinical relevance of Advanced Glycation Endproducts for vascular surgery**
Meerwaldt R. et al. *Eur J Vasc Endovasc Surg.* 2008; 38,125-131
78. **Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products.**
Mulder DJ. et al. *Atherosclerosis.* 2007:197:217-223
79. **Clinical and prognostic value of Advanced Glycation End-products (AGEs) in chronic heart failure.**
Hartog J. et al *Eur J Heart Failure* 2007;9:1146-55
80. **Skin Autofluorescence is an independent marker for Acute Myocardial Infarction**
Mulder DJ, et al. *Circulation*: 2005; 112:II-371.

AGE Reader in renal disease

81. **Comparing changes in plasma and skin autofluorescence in low-flux versus high-flux hemodialysis.**
Ramsauer B. et al. *Int J Artif Organs*. 2015 (Epub)
82. **Skin Autofluorescence Is Associated with Endothelial Dysfunction in Uremic Subjects on Hemodialysis.**
Wang CC. et al. *PLoS One*. 2016 Jan 25;11(1):e0147771.
83. **Skin autofluorescence advanced glycosylation end products (AGEs) as an independent predictor of mortality in high flux haemodialysis and haemodialysis patients.**
Nongnuch A. et al. *Nephrology (Carlton)*. 2015 May 25.
84. **The effect of vegetarian diet on skin autofluorescence measurements in haemodialysis patients.**
Nongnuch A. et al. *Br J Nutr*. 2015 Mar 12;1-4. (Epub)
85. **Skin Autofluorescence Is a Predictor of Cardiovascular Disease in Chronic Kidney Disease Patients.**
Furuya F. et al. *Ther Apher Dial*. 2014 Dec 29.
86. **Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis.**
Siriopol D. et al. *Int Urol Nephrol*. 2014 Nov 26.
87. **Skin autofluorescence as a novel marker of vascular damage in children and adolescents with chronic kidney disease.**
Makulska I. et al. *Pediatr Nephrol*. 2014 Nov 20.
88. **Skin autofluorescence associates with vascular calcification in chronic kidney disease.**
Maku A.Y. et al. *Arterioscler Thromb Vasc Biol*. 2014 Aug;34(8):1784-90
89. **Skin Autofluorescence and All-Cause Mortality in Stage 3 CKD.**
Fraser S.D. et al. *Clin J Am Soc Nephrol*. 2014 May 29. Epub
90. **Skin Autofluorescence Predicts Cardiovascular Mortality in Patients on Chronic Hemodialysis.**
Kimura H. et al. *Ther Apher Dial*. 2014 Jan 24
91. **Skin autofluorescence is associated with the progression of chronic kidney disease: a prospective observational study.**
Tanaka K. et al. *PLoS One*. 2013 Dec 12;8(12):e83799.
92. **Skin and Plasma Autofluorescence During Hemodialysis: A Pilot Study.**
Graaff R. et al. *Artif Organs*. 2013 Oct 29.
93. **Tissue Advanced Glycation End Product Deposition after Kidney Transplantation.**
Crowley LE et al. *Nephron Clin Pract*. 2013 Oct 15;124(1-2):54-59.
94. **Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review.**
Arsov S. et al. *Clin Chem Lab Med*. 2013 Apr 4:1-10.
95. **Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis.**
Jiang J. et al. *Atherosclerosis*. 2012 Sep;224(1):187-94.
96. **Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease.**
Siriopol I. et al. *Pediatr Nephrol*. 2012 Sep 15. (Epub)
97. **Factors influencing skin autofluorescence of patients with peritoneal dialysis.**
Mácsai E. et al. *Acta Physiol Hung*. 2012 Jun;99(2):216-22.
98. **Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in hemodialysis patients.**
Adachi T. et al. *Nephrology (Carlton)*. 2012 Jul 13. doi: 10.1111/j.1440-1797.2012.01642.x.
99. **Skin Autofluorescence: A Pronounced Marker of Mortality in Hemodialysis Patients.**
Gerrits E. et al. *Nephron Extra*. 2012 Jan;2(1):184-191.

- 100. Advanced oxidation protein products and advanced glycation end products in children and adolescents with chronic renal insufficiency.**
Sebeková K. J Ren Nutr. 2012 Jan;22(1):143-8.
- 101. Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients.** Oleniuc M. et al. Int Urol Nephrol. 2011 Oct;44(5):1441-9.
- 102. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3.**
McIntyre N.J. et al. Clin J Am Soc Nephrol. 2011 Oct;6(10):2356-63.
- 103. Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients.**
Nagano M. et al. Nephrology (Carlton). 2011 Mar;16(3):299-303
- 104. Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease.**
Smit AJ. et al. Curr Opin Nephrol Hypertens, 2010; 19(6):527-33.
- 105. Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients.**
Tanaka K. et al. Nephrol Dial Transplant. doi: 10.1093/ndt/gfq369
- 106. Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease.**
Ueno H et al. Metabolism, 2010, doi: 10.1016/j.metabol.2010.04.001
- 107. Tissue-Advanced Glycation End Product Concentration in Dialysis Patients**
McIntyre et al; CJASN, 2010; 5(1): 51-55
- 108. Does hepatitis C increase the accumulation of advanced glycation end products in haemodialysis patients?**
Arsov S. et al. Nephrol Dial Transplant 2009; 25(3): 885-891
- 109. Skin-Autofluorescence Is an Independent Predictor of Graft Loss in Renal Transplant Recipients**
Hartog J. et al, Transplantation • Volume 87, Number 7, April 15, 2009
- 110. Advanced Glycation End Products in Renal Failure: An Overview**
Noordzij M. et al, Journal of Renal Care 2008
- 111. AGEs, autofluorescence and renal failure**
Gerrits E. et al. Nephrology Dialysis and Transplantation November 25, 2008
- 112. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease**
Ueno H. et al: Metabolism Clinical and Experimental 57 (2008) 1452–1457
- 113. Skin Autofluorescence, a measure of tissue advanced glycation endproducts (AGEs), is related to the diastolic function of dialysis patients**
Hartog J. et al. Journal of Cardiac Failure. 2008; 14(7): 596-602
- 114. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients**
Hartog JW, et al. Nephrol Dial Transpl 2006 Aug;21(8):2263-9
- 115. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation endproducts, predicts mortality in hemodialysis patients**
Meerwaldt R, et al. J Am Soc Nephrol 2005;16:3687-93.
- 116. Skin autofluorescence, a noninvasive measure of advanced glycation end product accumulation, is a predictor of mortality in hemodialysis patients**
Meerwaldt R, et al. Ann N Y Acad Sci 2005;1043:911.
- 117. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease.**
Hartog JW. et al. Ann N Y Acad Sci. 2005 Jun;1043:299-307.
- 118. Advanced glycation endproducts in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction**
Hartog J. et al. Am J Kidn Dis 2004; 43:966-975

AGE Reader in other diseases

- 119. Relationship between advanced glycation end-product accumulation and low skeletal muscle mass in Japanese men and women.**
Kato M. et al. *Geriatr Gerontol Int.* 2016 Apr 27. Epub.
- 120. Advanced glycation endproducts and their receptor in different body compartments in COPD.**
Hoonhorst S.J. et al. *Respir Res.* 2016 Apr 26; 17:46.
- 121. The association between systemic oxidative stress and ocular blood flow in patients with normal-tension glaucoma.**
Himori N. et al. *Graefes Arch Clin Exp Ophthalmol.* 2016 Feb;254(2):333-41.
- 122. Skin Autofluorescence in Systemic Sclerosis Is Related to the Disease and Vascular Damage: A Cross-Sectional Analytic Study of Comparative Groups.**
Dadoniene J. et al. *Dis Markers.* 2015;2015:837470. Epub
- 123. Traditional and emerging indicators of cardiovascular risk in chronic obstructive pulmonary disease.**
John M. et al. *Chron Respir Dis.* 2016 Mar 10.
- 124. A new gender-specific model for skin autofluorescence risk stratification.**
Ahmad M.S. et al. *Sci Rep.* 2015 May 14;5:10198.
- 125. Achilles tendons in people with type 2 diabetes show mildly compromised structure: an ultrasound tissue characterisation study.**
de Jonge S. et al. *Br J Sports Med.* 2015 Jan 13 (Epub)
- 126. Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients?**
de Groot L. et al. *Rheumatology (Oxford).* 2015 Jan 12 (Epub)
- 127. Advanced glycation end products in the skin are enhanced in COPD.**
Hoonhorst S.J. et al. *Metabolism.* 2014 Jun 13. Epub
- 128. Life-long endurance running is associated with reduced glycation and mechanical stress in connective tissue.**
Couppe C. et al. *Age (Dordr).* 2014 Aug;36(4):9665.
- 129. Plasma AGEs and skin autofluorescence are increased in COPD.**
Gopal P. et al. *Eur Respir J.* 2013 May 3. [Epub ahead of print]
- 130. Increased advanced glycation end-products (AGEs) assessed by skin autofluorescence in schizophrenia.**
Kouidrat Y. et al. *J Psychiatr Res.* 2013 Apr 21.
- 131. Local differences in skin autofluorescence may not reflect similar differences in oxidative stress exposure.**
Hetteema M. et al. *J Rheumatol.* 2013 Feb;40(2):206.
- 132. Vascular Aspects of Fabry Disease in Relation to Clinical Manifestations and Elevations in Plasma Globotriaosylsphingosine.**
Rombach S.M. et al. *Hypertension.* 2012 Aug 6. (Epub)
- 133. Advanced Glycation Endproducts are increased in RA patients with controlled disease.**
de Groot L. et al. *Arthritis Res Ther.* 2011 Dec 14;13(6):R205.
- 134. Increased skin autofluorescence after colorectal operation reflects surgical stress and postoperative outcome.**
Pol H.W. et al. *Am J Surg.* 2011 Nov;202(5):583-9.

- 135. Skin autofluorescence, as marker of accumulation of advanced glycation endproducts and of cumulative metabolic stress, is not increased in patients with systemic sclerosis.**
Hetteema M.E. et al. *Int J Rheumatol.* 2011. Epub
- 136. Skin advanced glycation end-product accumulation is negatively associated with calcaneal osteo-sono assessment index among non-diabetic adult Japanese men.**
Momma H. *Osteoporos Int.* 2011 Sep 8. Epub
- 137. Skin autofluorescence is high in patients with cirrhosis - further arguing for the implication of Advanced Glycation End products.**
Maury E. et al. *J Hepatol.* 2011 May;54(5):1079-80.
- 138. Skin advanced glycation end product accumulation and muscle strength among adult men.**
Momma H. et al; *Eur J Appl Physiol.* 2010 (Epub)
- 139. Skin Autofluorescence as Marker of Tissue Advanced Glycation End-Products Accumulation in Formerly Preeclamptic Women.**
Coffeng S.M. et al. *Hypertens Pregnancy;* 2010, Epub
- 140. Accumulation of advanced glycation end (AGEs) products in intensive care patients: an observational, prospective study.**
Greven W. et al. *BMC Clinical Pathology;* 2010: 10 (4)
- 141. Increased accumulation of advanced glycation endproducts in patients with Wegener's granulomatosis.**
Leeuw de K et al. *Ann Rheum Dis.* 2009; 69(3): 625-U191
- 142. Skin autofluorescence is increased in systemic lupus erythematosus but not reflected by plasma levels advanced glycation endproducts**
Nienhuis H. et al: *Rheumatology.* 2008; 47(10): 1554-1558
- 143. Skin autofluorescence is increased in systemic lupus erythematosus but not reflected by plasma levels of advanced glycation endproducts**
Nienhuis H. et al. *Rheumatology;* 2008; 47(10): 1554-1558
- 144. Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia**
den Hollander NC. et al. *J Inherit Metab Dis.* 2007. epub ahead of print
- 145. Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus.**
de Leeuw K. et al. *Rheumatol* 2007;45:1551-1556.
- 146. Skin autofluorescence, a marker of advanced glycation end products and oxidative stress, is increased in recently preelamptic women**
Blaauw J. et al. *Am J Obstet Gynecol.* 2006 Sep;195(3):717-22.
- 147. Enhanced skin autofluorescence as a marker for oxidative stress in sepsis, a pilot study.**
Mulder DJ, et al. *Eur Soc Intensive Care Medicine* 2004

AGE Reader (technical) validation

- 148. Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study.**
van Waateringe R. et al. *Eur J Clin Invest.* 2016 Mar 22. Epub.
- 149. Body mass index, chronological age and hormonal status are better predictors of biological skin age than arm skin autofluorescence in healthy women who have never smoked.**
Randag A.C. et al. *Br J Dermatol.* 2015 Jul 25.
- 150. The skin autofluorescence reflects the posttranslational glycation grade of the matrix protein collagen.**
Jacobs K. et al. *Free Radic Biol Med.* 2014 Oct;75 Suppl 1:S34

- 151. GWAS identifies an NAT2 acetylator status tag single nucleotide polymorphism to be a major locus for skin fluorescence.**
Eny K.M. et al. Diabetologia. 2014 Aug;57(8):1623-34.
- 152. Reference values of skin autofluorescence as an estimation of tissue accumulation of advanced glycation end products in a general Slovak population.**
Klenovics KS, Diabet Med. 2013 Sep 30. doi: 10.1111/dme.12326. (Epub).
- 153. Reference values for the Chinese population of skin autofluorescence as a marker of advanced glycation end products accumulated in tissue.**
Yue X. et al. Diabet Med. 2011 Jul;28(7):818-23.
- 154. Dermal factors influencing measurement of skin autofluorescence.**
Noordzij M.J. et al. Diabetes Technol Ther. 2011 Feb;13(2):165-70
- 155. Skin color independent assessment of aging using skin autofluorescence**
Koetsier M. et al. Optics Express, 2010 ;18(14):14416-29
- 156. Reference Values of Skin Autofluorescence.**
Koetsier M. et al. Diabetes Technology & Therapeutics 2010; 12(5):399-403
- 157. Skin autofluorescence for the risk assessment of chronic complications in diabetes: a broad excitation range is sufficient**
Koetsier M. et al: Optics Express. 2009; 17(2): 509-519
- 158. Skin autofluorescence increases postprandially in human subjects**
Stirban A. et al. Diabetes Technology & Therapeutics 2008: 10:200-5
- 159. The Effect of Aggressive Versus Conventional Lipid-lowering Therapy on Markers of Inflammatory and Oxidative Stress.**
Mulder DJ. et al. Cardiovasc Drugs Ther. 2007 Apr;21(2):91-7.
- 160. Skin Autofluorescence, a Novel Marker for Glycation and Oxidative Stress derived Advanced Glycation Endproducts. An Overview of Current Clinical Studies, Evidence and Limitations**
Mulder DJ, et al. Diabetes Technology and Therapeutics 2006; 8:523-535.
- 161. Simple noninvasive measurement of skin autofluorescence**
Meerwaldt R, et al. Ann N Y Acad Sci. 2005;1043:290-298.
- 162. Instrumentation for the measurement of Autofluorescence in the human skin**
Graaff R et al. Proc. of SPIE Vol. 5692 (SPIE, Bellingham, WA, 2005). pp. 111-118.
- 163. Simple non-invasive assessment of advanced glycation endproducts accumulation**
Meerwaldt R et al. Diabetologia 2004; 47:1324-1330
-

For more information please visit:

www.diagnoptics.com

www.age-reader.com